Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label prospective study of leflunomide plus topical corticosteroids for bullous pemphigoid
2007-003545-32Phase 2Active
- Sponsor
- CHU de Limoges
- Start
- Jul 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of leflunomide in Bullous Pemphigoid (BP), sponsored by CHU de Limoges. Primary endpoint: Clinical complete remission at 6 months. Started Jul 2007; status: active.
02
Drugs
leflunomide
03
Conditions
Bullous Pemphigoid (BP)
Beyond the preview
Go deeper on 2007-003545-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003545-32.